TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 4157.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
TaiGen Biopharmaceuticals Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
TaiGen Biopharmaceuticals Holdings Limited’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -NT$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow TaiGen Biopharmaceuticals Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NT$10.70M-97.47% vs estimate |
| Q1 2025 | May 14, 2025 | -NT$0.03-103.09% vs estimate | NT$10.88M-98.86% vs estimate |
|---|
| Q4 2024 | Mar 13, 2025 | -NT$0.03-114.29% vs estimate | NT$10.49M-96.85% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -NT$0.10-137.04% vs estimate | NT$8.61M-97.4% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$48.85-NT$0.90 (-1.81%)
Medigen Vaccine Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 32.34% below the high.
NT$57.40-NT$2.60 (-4.33%)
TaiMed Biologics Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.87% below the high.
NT$17.20-NT$0.30 (-1.71%)
Adimmune Corporation’s quoted price sits in the lower half of its reported 52-week range, 23.56% below the high.
NT$24.60-NT$0.20 (-0.81%)
Formosa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.13% below the high.
NT$23.00-NT$1.05 (-4.37%)
Advagene Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
NT$11.95-NT$0.60 (-4.78%)
TaiRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.62% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
